'People, Infrastructure and Processes that Differ Remarkably from Competitors'

Dr. Rolf Kuropka, managing director, Krahn Chemie
Dr. Rolf Kuropka, managing director, Krahn Chemie

What kind of growth do you aspire to in the next few years; in which sectors, markets or regions do you see significant growth opportunities?

Krahn Chemie will consequently follow its growth strategy: regional expansion to countries attractive for distributors and strengthening of the product portfolio of the segments Krahn Chemie is active in, i.e., coatings and construction chemicals, plastics, rubber, technical ceramics, adhesives, and lubricants. We still believe that even in a quite mature market like the EU, a company can gain additional market share by offering people, infrastructure and processes that differ remarkably from competitors.

How do you intend to implement these plans and seize these opportunities?

With the acquisition of the ICH Benelux Group in 2013 and more recently Pietro Carini in Italy, Krahn Chemie took two major steps to expand its market position in Europe and to strengthen its portfolio and competencies. We will continue to follow this path, and we also go on winning attractive distributions rights of the tier 1 suppliers of the world. Our central laboratory in Bottrop as well as local laboratories in the main region will support our technically driven approach. The target is to become the preferred specialty chemical distributor in Europe.

 

Company

Krahn Chemie

Mühlenhagen 35
20539 Hamburg
Germany

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.